AWS
VTGN icon

Atria Wealth Solutions’s VistaGen Therapeutics VTGN Stock Holding History

Atria Wealth Solutions’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-333
Closed -$1.03K – 1959
2022
Q4 		$1.03K Hold
333
– – ﹤0.01% 1796
2022
Q3 		$1.52K Hold
333
– – ﹤0.01% 1741
2022
Q2 		$9K Hold
333
– – ﹤0.01% 1623
2022
Q1 		$12K Buy
+333
New +$14.5K ﹤0.01% 1718

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Atria Wealth Solutions's VTGN Position: Q1 2023 in Review

Atria Wealth Solutions sold out of VistaGen Therapeutics (VTGN) in Q1 2023, closing a stake of 333 shares — an estimated $1.03K sold.

Atria Wealth Solutions first reported a position in VTGN in Q1 2022 and held it in 4 quarters. The position peaked at $12K in Q1 2022. 83 funds tracked by Wall St. Rank hold VTGN as of Q1 2023.

  • Atria Wealth Solutions reported no remaining VistaGen Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Atria Wealth Solutions sold 333 VistaGen Therapeutics shares in Q1 2023, an estimated $1.03K.
  • Atria Wealth Solutions first reported a position in VistaGen Therapeutics in Q1 2022 and held it in 4 quarters.
  • Atria Wealth Solutions's VistaGen Therapeutics position peaked at $12K in Q1 2022.
  • 83 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2023.

Based on Atria Wealth Solutions's 13F filing for Q1 2023, filed 10 May 2023.